In spite of plummeting valuation, 23andMe still aims to pivot into biotech

23andMe has seen its valuation plummet from $6 billion to close to zero, with the Nasdaq threatening to delist the company’s stock. Still, company leaders have high hopes for medical research and a pivot to biotech. Rolfe Winkler has been writing about what happened for The Wall Street Journal, and discussed the company’s financial woes and future roadmap with Marketplace’s Lily Jamali.

Om Podcasten

Every weekday, host Kai Ryssdal helps you make sense of the day's business and economic news — no econ degree or finance background required. "Marketplace" takes you beyond the numbers, bringing you context. Our team of reporters all over the world speak with CEOs, policymakers and regular people just trying to get by.